Prostate cancer patients who have a prostate-specific antigen value of less than or equal to 1.5 at two years after external beam radiation therapy are less likely to have a cancer recurrence and cancer-related death, according to a new study.
Prostate cancer patients who have a prostate-specific antigen value of less than or equal to 1.5 at two years after external beam radiation therapy are less likely to have a cancer recurrence and cancer-related death, according to a new study.